Publicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (40)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  3. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

  4. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  5. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease

    Gastroenterologia y Hepatologia

  6. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  2. Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 439-445

  3. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  4. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  5. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  6. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort

    Scandinavian Journal of Gastroenterology

  7. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

  8. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Vol. 55, Núm. 1, pp. 46-52

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases

  3. Erratum: Re-induction with Intravenous Ustekinumab in Patients with Crohn's Disease and a Loss of Response to This Therapy (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab015)

    Inflammatory Bowel Diseases

  4. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  5. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  6. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736